AustralieFrV1, PascalFrancis, Curation, bibRecord, 005523

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Identifieur interne : 005523 ( PascalFrancis/Curation ); précédent : 005522; suivant : 005524

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Auteurs : A. M. Evens [États-Unis] ; S. Choquet [France] ; A. R. Kroll-Desrosiers [États-Unis] ; D. Jagadeesh [États-Unis] ; S. M. Smith [États-Unis] ; F. Morschhauser [France] ; V. Leblond [France] ; R. Roy [États-Unis] ; B. Barton [États-Unis] ; L. I. Gordon [États-Unis] ; M. K. Gandhi [Australie] ; D. Dierickx [Belgique] ; D. Schiff [États-Unis] ; T. M. Habermann [États-Unis] ; R. Trappe [Allemagne]

Source :

American journal of transplantation : (Print) [ 1600-6135 ] ; 2013.

RBID : Pascal:13-0235169

Descripteurs français

Pascal (Inist)
- Syndrome lymphoprolifératif posttransplantation, Primaire, Système nerveux central, Syndrome lymphoprolifératif, International, Monde, Lymphome, Compte rendu, Etude cas, Rituximab, Pronostic, Immunodépresseur, Immunothérapie, Anticorps monoclonal, Anticancéreux, Immunomodulateur, Traitement, Antigène CD20, Hémopathie maligne lymphoïde.

English descriptors

KwdEn :
- Antineoplastic agent, Case study, Central nervous system, Immunomodulator, Immunosuppressive agent, Immunotherapy, International, Lymphoid neoplasm, Lymphoma, Lymphoproliferative syndrome, Monoclonal antibody, Posttransplant lymphoproliferative disorder, Primary, Prognosis, Report, Rituximab, Treatment, World.

Abstract

We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.

A01	`01`	`1`		`@0 1600-6135`
A03		`1`		`@0 Am. j. transplant. : (Print)`
A05				`@2 13`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era`
A11	`01`	`1`		`@1 EVENS (A. M.)`
A11	`02`	`1`		`@1 CHOQUET (S.)`
A11	`03`	`1`		`@1 KROLL-DESROSIERS (A. R.)`
A11	`04`	`1`		`@1 JAGADEESH (D.)`
A11	`05`	`1`		`@1 SMITH (S. M.)`
A11	`06`	`1`		`@1 MORSCHHAUSER (F.)`
A11	`07`	`1`		`@1 LEBLOND (V.)`
A11	`08`	`1`		`@1 ROY (R.)`
A11	`09`	`1`		`@1 BARTON (B.)`
A11	`10`	`1`		`@1 GORDON (L. I.)`
A11	`11`	`1`		`@1 GANDHI (M. K.)`
A11	`12`	`1`		`@1 DIERICKX (D.)`
A11	`13`	`1`		`@1 SCHIFF (D.)`
A11	`14`	`1`		`@1 HABERMANN (T. M.)`
A11	`15`	`1`		`@1 TRAPPE (R.)`
A14	`01`			`@1 Division of Hematology/Oncology, The University of Massachusetts Medical School @2 Worcester, MA @3 USA @Z 1 aut. @Z 4 aut.`
A14	`02`			`@1 Hematology, Hospital Pitie-Salpetriere @2 Paris @3 FRA @Z 2 aut. @Z 7 aut.`
A14	`03`			`@1 Ouantitative Health Sciences, The University of Massachusetts @2 Worcester, MA @3 USA @Z 3 aut. @Z 9 aut.`
A14	`04`			`@1 Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals @2 Chicago, IL @3 USA @Z 5 aut.`
A14	`05`			`@1 Hematology, Lille University Hospital @2 Paris @3 FRA @Z 6 aut.`
A14	`06`			`@1 Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University @2 Chicago, IL @3 USA @Z 8 aut. @Z 10 aut.`
A14	`07`			`@1 Princess Alexandra Hospital @2 Brisbane, Old @3 AUS @Z 11 aut.`
A14	`08`			`@1 Department of Hematology, University Hospitals Leuven @2 Leuven @3 BEL @Z 12 aut.`
A14	`09`			`@1 Division of Neuro-Oncology, University of Virginia @2 Charlottesville, VA @3 USA @Z 13 aut.`
A14	`10`			`@1 Division of Hematology, Mayo Clinic @2 Rochester, MN @3 USA @Z 14 aut.`
A14	`11`			`@1 Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel @2 Kiel @3 DEU @Z 15 aut.`
A20				`@1 1512-1522`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 27587 @5 354000503626080160`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 38 ref.`
A47	`01`	`1`		`@0 13-0235169`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 American journal of transplantation : (Print)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.
C02	`01`	`X`		`@0 002B25`
C02	`02`	`X`		`@0 002B19B`
C03	`01`	`X`	`FRE`	`@0 Syndrome lymphoprolifératif posttransplantation @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Posttransplant lymphoproliferative disorder @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Síndrome linfoproliferativo postrasplante @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Primaire @5 02`
C03	`02`	`X`	`ENG`	`@0 Primary @5 02`
C03	`02`	`X`	`SPA`	`@0 Primario @5 02`
C03	`03`	`X`	`FRE`	`@0 Système nerveux central @5 03`
C03	`03`	`X`	`ENG`	`@0 Central nervous system @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso central @5 03`
C03	`04`	`X`	`FRE`	`@0 Syndrome lymphoprolifératif @2 NM @5 04`
C03	`04`	`X`	`ENG`	`@0 Lymphoproliferative syndrome @2 NM @5 04`
C03	`04`	`X`	`SPA`	`@0 Linfoproliferativo síndrome @2 NM @5 04`
C03	`05`	`X`	`FRE`	`@0 International @5 05`
C03	`05`	`X`	`ENG`	`@0 International @5 05`
C03	`05`	`X`	`SPA`	`@0 Internacional @5 05`
C03	`06`	`X`	`FRE`	`@0 Monde @2 NG @5 06`
C03	`06`	`X`	`ENG`	`@0 World @2 NG @5 06`
C03	`06`	`X`	`SPA`	`@0 Mundo @2 NG @5 06`
C03	`07`	`X`	`FRE`	`@0 Lymphome @5 07`
C03	`07`	`X`	`ENG`	`@0 Lymphoma @5 07`
C03	`07`	`X`	`SPA`	`@0 Linfoma @5 07`
C03	`08`	`X`	`FRE`	`@0 Compte rendu @5 08`
C03	`08`	`X`	`ENG`	`@0 Report @5 08`
C03	`08`	`X`	`SPA`	`@0 Informe @5 08`
C03	`09`	`X`	`FRE`	`@0 Etude cas @5 09`
C03	`09`	`X`	`ENG`	`@0 Case study @5 09`
C03	`09`	`X`	`SPA`	`@0 Estudio caso @5 09`
C03	`10`	`X`	`FRE`	`@0 Rituximab @2 NK @2 FR @5 10`
C03	`10`	`X`	`ENG`	`@0 Rituximab @2 NK @2 FR @5 10`
C03	`10`	`X`	`SPA`	`@0 Rituximab @2 NK @2 FR @5 10`
C03	`11`	`X`	`FRE`	`@0 Pronostic @5 11`
C03	`11`	`X`	`ENG`	`@0 Prognosis @5 11`
C03	`11`	`X`	`SPA`	`@0 Pronóstico @5 11`
C03	`12`	`X`	`FRE`	`@0 Immunodépresseur @5 12`
C03	`12`	`X`	`ENG`	`@0 Immunosuppressive agent @5 12`
C03	`12`	`X`	`SPA`	`@0 Inmunodepresor @5 12`
C03	`13`	`X`	`FRE`	`@0 Immunothérapie @5 13`
C03	`13`	`X`	`ENG`	`@0 Immunotherapy @5 13`
C03	`13`	`X`	`SPA`	`@0 Inmunoterapia @5 13`
C03	`14`	`X`	`FRE`	`@0 Anticorps monoclonal @5 17`
C03	`14`	`X`	`ENG`	`@0 Monoclonal antibody @5 17`
C03	`14`	`X`	`SPA`	`@0 Anticuerpo monoclonal @5 17`
C03	`15`	`X`	`FRE`	`@0 Anticancéreux @5 25`
C03	`15`	`X`	`ENG`	`@0 Antineoplastic agent @5 25`
C03	`15`	`X`	`SPA`	`@0 Anticanceroso @5 25`
C03	`16`	`X`	`FRE`	`@0 Immunomodulateur @5 26`
C03	`16`	`X`	`ENG`	`@0 Immunomodulator @5 26`
C03	`16`	`X`	`SPA`	`@0 Inmunomodulador @5 26`
C03	`17`	`X`	`FRE`	`@0 Traitement @5 27`
C03	`17`	`X`	`ENG`	`@0 Treatment @5 27`
C03	`17`	`X`	`SPA`	`@0 Tratamiento @5 27`
C03	`18`	`X`	`FRE`	`@0 Antigène CD20 @4 INC @5 86`
C03	`19`	`X`	`FRE`	`@0 Hémopathie maligne lymphoïde @4 CD @5 96`
C03	`19`	`X`	`ENG`	`@0 Lymphoid neoplasm @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Hémopathie maligne @2 NM @5 37`
C07	`01`	`X`	`ENG`	`@0 Malignant hemopathy @2 NM @5 37`
C07	`01`	`X`	`SPA`	`@0 Hemopatía maligna @2 NM @5 37`
C07	`02`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`02`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`02`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`03`	`X`	`FRE`	`@0 Anti-CD20 @4 INC @5 87`
N21				`@1 217`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000953

Links to Exploration step

Pascal:13-0235169

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era</title>
<author><name sortKey="Evens, A M" sort="Evens, A M" uniqKey="Evens A" first="A. M." last="Evens">A. M. Evens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Choquet, S" sort="Choquet, S" uniqKey="Choquet S" first="S." last="Choquet">S. Choquet</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Kroll Desrosiers, A R" sort="Kroll Desrosiers, A R" uniqKey="Kroll Desrosiers A" first="A. R." last="Kroll-Desrosiers">A. R. Kroll-Desrosiers</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Jagadeesh, D" sort="Jagadeesh, D" uniqKey="Jagadeesh D" first="D." last="Jagadeesh">D. Jagadeesh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Smith, S M" sort="Smith, S M" uniqKey="Smith S" first="S. M." last="Smith">S. M. Smith</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F." last="Morschhauser">F. Morschhauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Hematology, Lille University Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Leblond, V" sort="Leblond, V" uniqKey="Leblond V" first="V." last="Leblond">V. Leblond</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Roy, R" sort="Roy, R" uniqKey="Roy R" first="R." last="Roy">R. Roy</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Barton, B" sort="Barton, B" uniqKey="Barton B" first="B." last="Barton">B. Barton</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Gordon, L I" sort="Gordon, L I" uniqKey="Gordon L" first="L. I." last="Gordon">L. I. Gordon</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Gandhi, M K" sort="Gandhi, M K" uniqKey="Gandhi M" first="M. K." last="Gandhi">M. K. Gandhi</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Princess Alexandra Hospital</s1>
<s2>Brisbane, Old</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Dierickx, D" sort="Dierickx, D" uniqKey="Dierickx D" first="D." last="Dierickx">D. Dierickx</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Hematology, University Hospitals Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Schiff, D" sort="Schiff, D" uniqKey="Schiff D" first="D." last="Schiff">D. Schiff</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Division of Neuro-Oncology, University of Virginia</s1>
<s2>Charlottesville, VA</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Habermann, T M" sort="Habermann, T M" uniqKey="Habermann T" first="T. M." last="Habermann">T. M. Habermann</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Division of Hematology, Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Trappe, R" sort="Trappe, R" uniqKey="Trappe R" first="R." last="Trappe">R. Trappe</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0235169</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0235169 INIST</idno>
<idno type="RBID">Pascal:13-0235169</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000953</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005523</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era</title>
<author><name sortKey="Evens, A M" sort="Evens, A M" uniqKey="Evens A" first="A. M." last="Evens">A. M. Evens</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Choquet, S" sort="Choquet, S" uniqKey="Choquet S" first="S." last="Choquet">S. Choquet</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Kroll Desrosiers, A R" sort="Kroll Desrosiers, A R" uniqKey="Kroll Desrosiers A" first="A. R." last="Kroll-Desrosiers">A. R. Kroll-Desrosiers</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Jagadeesh, D" sort="Jagadeesh, D" uniqKey="Jagadeesh D" first="D." last="Jagadeesh">D. Jagadeesh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Smith, S M" sort="Smith, S M" uniqKey="Smith S" first="S. M." last="Smith">S. M. Smith</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F." last="Morschhauser">F. Morschhauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Hematology, Lille University Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Leblond, V" sort="Leblond, V" uniqKey="Leblond V" first="V." last="Leblond">V. Leblond</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Roy, R" sort="Roy, R" uniqKey="Roy R" first="R." last="Roy">R. Roy</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Barton, B" sort="Barton, B" uniqKey="Barton B" first="B." last="Barton">B. Barton</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Gordon, L I" sort="Gordon, L I" uniqKey="Gordon L" first="L. I." last="Gordon">L. I. Gordon</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Gandhi, M K" sort="Gandhi, M K" uniqKey="Gandhi M" first="M. K." last="Gandhi">M. K. Gandhi</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Princess Alexandra Hospital</s1>
<s2>Brisbane, Old</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Dierickx, D" sort="Dierickx, D" uniqKey="Dierickx D" first="D." last="Dierickx">D. Dierickx</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Hematology, University Hospitals Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Schiff, D" sort="Schiff, D" uniqKey="Schiff D" first="D." last="Schiff">D. Schiff</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Division of Neuro-Oncology, University of Virginia</s1>
<s2>Charlottesville, VA</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Habermann, T M" sort="Habermann, T M" uniqKey="Habermann T" first="T. M." last="Habermann">T. M. Habermann</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Division of Hematology, Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Trappe, R" sort="Trappe, R" uniqKey="Trappe R" first="R." last="Trappe">R. Trappe</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">American journal of transplantation : (Print)</title>
<title level="j" type="abbreviated">Am. j. transplant. : (Print)</title>
<idno type="ISSN">1600-6135</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">American journal of transplantation : (Print)</title>
<title level="j" type="abbreviated">Am. j. transplant. : (Print)</title>
<idno type="ISSN">1600-6135</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Case study</term>
<term>Central nervous system</term>
<term>Immunomodulator</term>
<term>Immunosuppressive agent</term>
<term>Immunotherapy</term>
<term>International</term>
<term>Lymphoid neoplasm</term>
<term>Lymphoma</term>
<term>Lymphoproliferative syndrome</term>
<term>Monoclonal antibody</term>
<term>Posttransplant lymphoproliferative disorder</term>
<term>Primary</term>
<term>Prognosis</term>
<term>Report</term>
<term>Rituximab</term>
<term>Treatment</term>
<term>World</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome lymphoprolifératif posttransplantation</term>
<term>Primaire</term>
<term>Système nerveux central</term>
<term>Syndrome lymphoprolifératif</term>
<term>International</term>
<term>Monde</term>
<term>Lymphome</term>
<term>Compte rendu</term>
<term>Etude cas</term>
<term>Rituximab</term>
<term>Pronostic</term>
<term>Immunodépresseur</term>
<term>Immunothérapie</term>
<term>Anticorps monoclonal</term>
<term>Anticancéreux</term>
<term>Immunomodulateur</term>
<term>Traitement</term>
<term>Antigène CD20</term>
<term>Hémopathie maligne lymphoïde</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1600-6135</s0>
</fA01>
<fA03 i2="1"><s0>Am. j. transplant. : (Print)</s0>
</fA03>
<fA05><s2>13</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>EVENS (A. M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CHOQUET (S.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KROLL-DESROSIERS (A. R.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>JAGADEESH (D.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SMITH (S. M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MORSCHHAUSER (F.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LEBLOND (V.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ROY (R.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>BARTON (B.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>GORDON (L. I.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>GANDHI (M. K.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>DIERICKX (D.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>SCHIFF (D.)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>HABERMANN (T. M.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>TRAPPE (R.)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Hematology/Oncology, The University of Massachusetts Medical School</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Hematology, Hospital Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Ouantitative Health Sciences, The University of Massachusetts</s1>
<s2>Worcester, MA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Departament of Medicine, Section of Hematology/Oncology, University of Chicago Hospitals</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Hematology, Lille University Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Princess Alexandra Hospital</s1>
<s2>Brisbane, Old</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Hematology, University Hospitals Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Division of Neuro-Oncology, University of Virginia</s1>
<s2>Charlottesville, VA</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Division of Hematology, Mayo Clinic</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Department of Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA20><s1>1512-1522</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>27587</s2>
<s5>354000503626080160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>38 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0235169</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>American journal of transplantation : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56- 29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B25</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B19B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Syndrome lymphoprolifératif posttransplantation</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Posttransplant lymphoproliferative disorder</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Síndrome linfoproliferativo postrasplante</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Primaire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Primary</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Primario</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Syndrome lymphoprolifératif</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>International</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>International</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Internacional</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Monde</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>World</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Mundo</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Lymphome</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Lymphoma</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Linfoma</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Compte rendu</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Report</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Informe</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Case study</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Rituximab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Rituximab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Rituximab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Immunodépresseur</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Immunosuppressive agent</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Inmunodepresor</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Immunothérapie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Immunotherapy</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Inmunoterapia</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Anticorps monoclonal</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Monoclonal antibody</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Anticuerpo monoclonal</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>25</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Immunomodulateur</s0>
<s5>26</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Immunomodulator</s0>
<s5>26</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Inmunomodulador</s0>
<s5>26</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Traitement</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Treatment</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>27</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Antigène CD20</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Hémopathie maligne lymphoïde</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Lymphoid neoplasm</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Anti-CD20</s0>
<s4>INC</s4>
<s5>87</s5>
</fC07>
<fN21><s1>217</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005523 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 005523 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:13-0235169
   |texte=   Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri